Abstract: Cycloheximide (CHX) is a naturally occurring glutarimide-containing polyketide first isolated from Streptomyces griseus. Widely recognized as a potent translation elongation inhibitor in eukaryotes, CHX exerts its effects by binding to the 60S subunit of the 80S ribosome, specifically at the E-site. While its high systemic toxicity has historically precluded its direct clinical use, recent advances in structural biology, particularly high-resolution cryo-electron microscopy (cryo-EM), have revitalized interest in CHX as a scaffold for rational drug design. This review explores the pharmacological profile of cycloheximide and its derivatives, focusing on their ability to induce apoptosis in malignant cells by depleting short-lived oncogenic proteins, their antiviral properties, and their potential as neuroprotective agents through the inhibition of FKBP12. Furthermore, we discuss the structure-activity relationship (SAR) of CHX, current therapeutic limitations, and future perspectives for developing analogues with improved efficacy and reduced toxicity.
1. Introduction
Cycloheximide (CHX), originally referred to as actidione, is the first discovered member of the glutarimide-containing polyketides (GPs). It was isolated from the bacterium Streptomyces griseus in 1947 [1] [2]. Structurally, CHX is characterized by a bipartite framework consisting of a six-membered glutarimide ring (2,6-piperidinedione) and a polyketide side chain containing a distinctive 3,5-dimethyl-2-oxocyclohexyl group [2]. As a potent cell toxin in eukaryotes, CHX has long been utilized as a standard biochemical reagent to halt protein synthesis [1]. Although its inherent toxicity has limited its direct application in human medicine, CHX remains a critical reference compound for understanding ribosomal inhibition and serves as a structural template for designing novel therapeutic agents targeting cancer apoptosis and neuroregeneration [1].
2. Pharmacological Activity
Cycloheximide and its derivatives exhibit a diverse range of biological activities, primarily stemming from their ability to halt protein translation:
Apoptosis and Anti-Cancer Activity: Cancer cells often develop an addiction to protein synthesis to fuel their metabolic and proliferative needs. By inhibiting the 80S ribosome, CHX rapidly depletes short-lived oncogenic and anti-apoptotic proteins, such as c-MYC, MCL-1, and XIAP. The rapid turnover of these proteins makes malignant cells particularly sensitive to translation inhibition, triggering a strong apoptotic response [1].
Neuroprotection and Neuroregeneration: Specific synthetic derivatives of cycloheximide have been evaluated for their neuroregenerative properties. Research has demonstrated that certain CHX analogues can act as potential inhibitors of the immunophilin FKBP12, a target associated with neuroprotection and nerve regeneration [1].
Antiviral and Antifungal Properties: CHX displays strong inhibitory activities against plant fungi and a broad spectrum of RNA and DNA viruses, including HIV-1, influenza, herpes simplex virus (HSV), and coronaviruses. It achieves this by blocking the protein synthesis required for viral replication and glycoprotein transport [2] [7].
3. Molecular Mechanism of Action
Cycloheximide interferes with protein synthesis by inhibiting the translocation step during translation elongation in eukaryotes [1]. It specifically targets the 60S subunit of the eukaryotic 80S ribosome, preventing the transfer RNA (tRNA) from leaving the exit site (E-site) [2].
Recent high-resolution (3.6 Å) cryo-EM studies of the human cytosolic ribosome in complex with CHX have provided precise atomic insights into this mechanism. CHX inserts into the ribosomal pocket similarly to an E-site tRNA, positioning itself between nucleotides G4370 and G4371. Within this pocket, the molecule interacts closely with the eukaryote-specific ribosomal protein eL42, forming critical contacts with residues such as Lys53, Pro54, and Phe56 [1].
At the cellular level, the stalling of translation by CHX has distinct effects on stress response mechanisms. Because CHX freezes ribosomes on messenger RNA, it prevents the liquid-liquid phase separation (LLPS) required for the formation of stress granules (SGs). However, it does not dismantle pre-existing "assemblysomes"—specialized, translationally paused ribosome-nascent chain complexes that are resistant to CHX and play roles in co-translational protein assembly and DNA damage responses [3].
4. Structure-Activity Relationship (SAR)
The biological activity of cycloheximide is highly dependent on its specific structural and stereochemical features:
Chirality: CHX possesses four chiral centers. SAR studies have shown that the stereoconfiguration is absolutely critical; modifications to these chiral centers result in a drastic loss of activity. The chirality must remain identical to the natural compound to maintain ribosomal inhibition [1] [2].
Cyclohexanone Moiety: Alterations to the 3,5-dimethyl-2-oxocyclohexyl group can modulate activity. While replacing a methyl group with a butyl chain does not significantly decrease activity, incorporating electrophilic groups (such as a benzyl ester) can improve protein synthesis inhibition by an order of magnitude, likely by facilitating new interactions with nearby lysine residues in the ribosomal pocket [1].
Antiviral Pharmacophores: For its antiviral activities, the 6-OH and 8-C=O groups on the CHX scaffold have been identified as essential active functional groups [2].
5. Current Limitations
The primary limitation of cycloheximide is its profound toxicity in eukaryotes. Because it indiscriminately targets the highly conserved 80S ribosome, its toxicity level is too high for direct therapeutic application in humans [1]. Historically, empirical attempts to synthesize CHX analogues in the 1960s and beyond failed to yield compounds with significantly enhanced bioactivity or a safer toxicity profile, leading to a decline in its clinical development [1].
6. Future Perspectives
The advent of high-resolution cryo-EM has revolutionized the potential for structure-guided drug design based on the CHX scaffold. By visualizing the exact binding pocket of CHX within the human 80S ribosome, chemists can now rationally design analogues that exploit unoccupied spaces. For instance, extending the 3,5-dimethyl-2-oxocyclohexyl moiety towards the E-site tRNA CCA end, or filling the space between CHX and the eL42 protein, offers a pathway to novel derivatives [1].
Ongoing rational design projects have already synthesized new CHX molecules displaying up to 50- to 100-fold improved anti-leukemic activity compared to the parental compound. If these derivatives can achieve a favorable therapeutic window by selectively targeting the heightened protein synthesis addiction of cancer cells (or specific "oncoribosomes"), CHX analogues could emerge as a powerful new class of adjuvant therapies for cancer and neurodegenerative diseases [1].
